全文获取类型
收费全文 | 12173篇 |
免费 | 676篇 |
国内免费 | 198篇 |
专业分类
耳鼻咽喉 | 46篇 |
儿科学 | 264篇 |
妇产科学 | 176篇 |
基础医学 | 2236篇 |
口腔科学 | 511篇 |
临床医学 | 745篇 |
内科学 | 2219篇 |
皮肤病学 | 132篇 |
神经病学 | 1111篇 |
特种医学 | 123篇 |
外国民族医学 | 4篇 |
外科学 | 1078篇 |
综合类 | 531篇 |
现状与发展 | 4篇 |
预防医学 | 411篇 |
眼科学 | 108篇 |
药学 | 2020篇 |
中国医学 | 276篇 |
肿瘤学 | 1052篇 |
出版年
2023年 | 127篇 |
2022年 | 229篇 |
2021年 | 324篇 |
2020年 | 284篇 |
2019年 | 376篇 |
2018年 | 350篇 |
2017年 | 304篇 |
2016年 | 282篇 |
2015年 | 343篇 |
2014年 | 640篇 |
2013年 | 981篇 |
2012年 | 477篇 |
2011年 | 579篇 |
2010年 | 433篇 |
2009年 | 469篇 |
2008年 | 539篇 |
2007年 | 504篇 |
2006年 | 506篇 |
2005年 | 426篇 |
2004年 | 390篇 |
2003年 | 379篇 |
2002年 | 318篇 |
2001年 | 299篇 |
2000年 | 283篇 |
1999年 | 302篇 |
1998年 | 285篇 |
1997年 | 218篇 |
1996年 | 248篇 |
1995年 | 227篇 |
1994年 | 222篇 |
1993年 | 172篇 |
1992年 | 164篇 |
1991年 | 129篇 |
1990年 | 119篇 |
1989年 | 106篇 |
1988年 | 108篇 |
1987年 | 72篇 |
1986年 | 97篇 |
1985年 | 111篇 |
1984年 | 114篇 |
1983年 | 82篇 |
1982年 | 69篇 |
1981年 | 71篇 |
1980年 | 59篇 |
1979年 | 36篇 |
1978年 | 33篇 |
1977年 | 28篇 |
1976年 | 24篇 |
1974年 | 27篇 |
1973年 | 26篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
2.
Summary— KR31080 (2-butyl-5-methyl-6-(1-oxopyridin-2-yl)-3-[[2'-(1H-tetrazol-5-yl) biphenyl-4-yl]methyl]-3H-imidazo[4,5-b] pyridine) is a potent inhibitor of angiotensin type 1 (AT1 ) receptors in rabbit aorta and human recombinant AT1 receptors. In the isolated rabbit thoracic aorta, KR31080 caused a nonparallel shift to the right of the concentration-response curves to angiotensin II (All) with decreased maximal response (pD'2 = 10.1 ± 0.1), but had no effect on the contractile response induced by norepinephrine. KR31080 inhibited specific [125 I]AII binding to rabbit aortic membranes (AT, receptors) and [125 I][Sar1 , Ile8 ]AII binding to human recombinant AT1 receptors in a concentration-dependent manner with IC50 values of 0.84 ± 0.08 nM and 1.92 ± 0.15 nM, respectively, but did not inhibit specific [125 I)AII binding to bovine cerebellum membranes (ÀT2 receptors). In the Scatchard analysis, KR31080 interacted with rabbit aortic AT1 receptors in a competitive manner, similar to losartan. These results demonstrate that KR31080 is a potent and AT1 selective angiotensin receptor antagonist which exerts a competitive antagonism in the [125 I]AII binding assay and insurmountable AT1 receptor antagonism in the functional study. 相似文献
3.
4.
5.
H. S. Pollinger M. D. Stegall J. M. Gloor S. B. Moore S. R. Degoey N. A. Ploeger W. D. Park H. S. Pollinger M. D. Stegall J. M. Gloor S. B. Moore S. R. Degoey N. A. Ploeger W. D. Park 《American journal of transplantation》2007,7(4):857-863
The immunologic risk associated with donor-specific antibodies (DSA) against Class II human leukocyte antigens (HLA) in kidney transplant (KTx) recipients is unclear. The aim of this study was to determine the outcome of KTx when DSA was detected only against HLA Class II. To isolate the impact of anti-Class II DSA, we retrospectively analyzed 12 KTx recipients who at baseline had a positive B-cell flow cytometric crossmatch (FXM) and a negative T-cell FXM. Using alloantibody specification analysis, 58.3% (7/12) had DSA against donor Class II and 41.7% had no demonstrable DSA. Biopsy-proven AMR occurred in 57% (4/7) in the Class II(+) group and 0% in the Class II(-) group (p > 0.05). Peritubular capillaries stained positive for C4d in 86% (6/7) of the Class II(+) patients and in 40% (2/5) of the Class II(-) patients (p > 0.05). One patient in the Class II(+) group lost their graft at 3 months to accelerated transplant glomerulopathy, while all other grafts were functioning 3-37 months posttransplant despite the persistence of anti-Class II DSA. We conclude that KTx recipients with clearly defined anti-Class II DSA are at risk for humoral rejection suggesting that desensitization and/or close posttransplant monitoring may be needed to prevent AMR. 相似文献
6.
Phase II clinical trials are performed to investigate whether a novel treatment shows sufficient promise of efficacy to justify its evaluation in a subsequent definitive phase III trial, and they are often also used to select the dose to take forward. In this paper we discuss different design proposals for a phase II trial in which three active treatment doses and a placebo control are to be compared in terms of a single‐ordered categorical endpoint. The sample size requirements for one‐stage and two‐stage designs are derived, based on an approach similar to that of Dunnett. Detailed computations are prepared for an illustrative example concerning a study in stroke. Allowance for early stopping for futility is made. Simulations are used to verify that the specified type I error and power requirements are valid, despite certain approximations used in the derivation of sample size. The advantages and disadvantages of the different designs are discussed, and the scope for extending the approach to different forms of endpoint is considered. Copyright © 2008 John Wiley & Sons, Ltd. 相似文献
7.
8.
S. Bereswill F. Fassbinder C. Völzing A. Covacci R. Haas M. Kist 《Medical microbiology and immunology》1998,186(4):177-187
Various strains of Helicobacter pylori were able to lyse erythrocytes from sheep, horse, and human when grown on blood agar. The hemolysis did not depend on the
production of the vacuolating cytotoxin VacA as demonstrated by the hemolytic behavior of an isogenic vacA-negative mutant strain. The hemolytic activity could be detected in cell-free supernatants and was not regulated by iron.
To isolate genes coding for proteins involved in the destruction of erythrocytes, a plasmid-based DNA library was screened
for expression of lytic activity on blood agar. This approach revealed that the H. pylori ribA gene confers hemolytic properties to Escherichia coli. The ribA gene encodes the enzyme GTP-cyclohydrolase II [EC 3.5.4.25] that catalyzes the initial step in the synthesis of riboflavin.
The predicted amino acid sequence of the H. pylori RibA protein showed a high degree of similarity to equivalent enzymes from microorganisms and from plants. The single gene
on a plasmid restored riboflavin synthesis in a ribA mutant of E. coli and induced hemolytic activity. Furthermore, ribA overexpression was associated with the production of a fluorescent yellow molecule that was not identical with riboflavin.
Hemolysis was also seen for the ribA gene from E. coli, indicating that this feature was not specific for the H. pylori gene. The presence of ribA in various H. pylori strains was confirmed by Southern blot hybridization and by polymerase chain reaction with specific primers. This analysis
revealed that microdiversity exists within the DNA region upstream from ribA, which was further confirmed by nucleotide sequence analysis.
Received: 25 July 1997 相似文献
9.
10.
汕头卫生检疫局空港处对汕头航空口岸—宗入境二级货包的监测过程及对有关运输工作人员作了放射知识问卷调查。从中发现。运输单位货物存放设施落后。有关工作人员放射卫生知识欠缺,对放射污染可能造成的危害缺乏正确的认识。为此,笔者提出了自己的看法,以期对放射监测工作的进一步完善提供参考。 相似文献